Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 23Carcinoma, Renal Cell 21Lung Neoplasms 11Neoplasm Metastasis 10Colorectal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Prostatic Neoplasms 8Neoplasms 8Hodgkin Disease 8Carcinoma, Hepatocellular 7Adenocarcinoma Of Esophagus 7Stomach Neoplasms 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Urinary Bladder Neoplasms 4Nasopharyngeal Carcinoma 4Multiple Myeloma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Carcinoma, Basal Cell 4Brain Neoplasms 4Anus Neoplasms 4Uterine Cervical Neoplasms 3Thyroid Neoplasms 3Sarcoma, Kaposi 3Oropharyngeal Neoplasms 3

Interventions

olaparib 1lutetium Lu 177 dotatate 1fluorodopa F 18 1cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Nivolumab × 30 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡